XOIs reduce the production of uric acid; ZURAMPIC increases renal excretion of uric acid by selectively inhibiting the action of URAT1, the UA transporter responsible for the majority of renal UA reabsorption. The dual-mechanism combination of ZURAMPIC plus an XOI (allopurinol or febuxostat) can address both inefficient excretion and overproduction of UA, thereby lowering sUA levels. The safety and efficacy of ZURAMPIC were established in three Phase III clinical trials that evaluated a once-daily dose of ZURAMPIC in combination with the XOI allopurinol or febuxostat compared to XOI alone. Visit www.zurampic.com for more information about ZURAMPIC. Important Safety Information WARNING: RISK OF ACUTE RENAL FAILURE MORE COMMON WHEN USED WITHOUT A XANTHINE OXIDASE INHIBITOR (XOI) — Acute renal failure has occurred with ZURAMPIC and was more common when ZURAMPIC was given alone — ZURAMPIC should be used in combination with an XOI Contraindications: Severe renal impairment (eCLcr less than 30 mL/min), end-stage renal disease, kidney transplant recipients, or patients on dialysis Tumor lysis syndrome or Lesch-Nyhan syndrome Warnings and Precautions: Read More Renal events: Adverse reactions related to renal function have occurred after initiating ZURAMPIC. A higher incidence was observed at the 400-mg dose, with the highest incidence occurring with monotherapy use. Monitor renal function at initiation and during therapy with ZURAMPIC, particularly in patients with eCLcr below 60 mL/min or with serum creatinine elevations 1.5 to 2 times the pre-treatment value, and evaluate for signs and symptoms of acute uric acid nephropathy. Interrupt treatment with ZURAMPIC if serum creatinine is elevated to greater than 2 times the pre-treatment value or if there are symptoms that may indicate acute uric acid nephropathy. ZURAMPIC should not be restarted without another explanation for the serum creatinine abnormalities. ZURAMPIC should not be initiated in patients with an eCLcr less than 45 mL/min. Cardiovascular events: In clinical trials, major adverse cardiovascular events (defined as cardiovascular deaths, non-fatal myocardial infarctions, or non-fatal strokes) were observed with ZURAMPIC.
For the original version including any supplementary images or video, visit http://finance.yahoo.com/news/ironwood-announces-u-availability-zurampic-113000736.html
5, 2016 /PRNewswire/ — StockNewsNow.com , The Official MicroCap News Source, today published an SNNLive Video Interview with Vincent Metcalfe, CFO of Falco Resources Ltd. ( FPC.V ), a junior resource exploration company and one of the largest claim holders in the Abitibi region of Quebec, according to the Company’s website (see here: www.falcores.com ). The video interview was recorded on Wednesday, September 14th, 2016 at the Precious Metals Summit 2016 in Beaver Creek, CO. Click the following link to watch the SNNLive Video Interview on StockNewsNow.com: You can follow Stock News Now on FACEBOOK , TWITTER , LINKEDIN , YOUTUBE , and STOCKTWITS Please review important disclosures on our website at: http://stocknewsnow.com/legal.php#disclaimer About Falco Resources Ltd. original siteFalco Resources Ltd.is one of the largest mineral claim holders in the Province of Quebec, with extensive land holdings in the Abitibi Greenstone Belt. Falco owns 74,000 hectares of land in theRouyn-Norandamining camp, which represents 70% of the entire camp and includes 13 former gold and base metal mine sites. Falco’s principal property is theHorne Mine, which was operated by Noranda from 1927 to 1976 and produced 11.6 million ounces of gold and 2.5 billion pounds of copper.Osisko Gold Royaltiesis the largest shareholder of the Company and currently owns 16.2% of the outstanding shares of the Company. Company description and for more information about Falco Resources Ltd., please visit: www.falcores.com About StockNewsNow.com StockNewsNow.com is a microcap financial news portal that features news and insights from the microcap and emerging growth financial community. StockNewsNow.com is a multimedia destination hub for information about microcap and emerging growth public and private companies, market events, news, bulletins, stock quotes, expert commentary and company profiles that feature SNN-produced video like SNNLive CEO video interviews, as well as their latest news and headlines. Users can engage directly and share the information provided through social media.
For the original version including any supplementary images or video, visit http://finance.yahoo.com/news/stocknewsnow-com-publishes-snnlive-video-123000203.html
Schizophrenia: It is a suspected autoimmune disease and is a mental disorder that causes abnormalities in the perception of the affected person. However, if it occurs then needs to be corrected surgically. Following safe sex practices and avoiding blood-to-blood contact in any way are the best measures to prevent HIV infections. It is a type of skin disorder which causes de pigmentation of the skin. Malay Rash – Causes and Treatment Malay rash is also known as butterfly rash because of the way it appears, mainly, on the face of a person. Massachusetts General Hospital University of Pittsburgh Medical enter UPC University of Pittsburgh Medical enter, Pittsburgh, is considered as the leading American health care provider and has been consistently featured in US News & World Report amongst the 20 best hospitals in America over the last few years. Skin Allergies: Skin allergies are similar to any other allergy, where only the immunological response is expressed through the skin. Clicking HereFifth Disease – The human parvovirus B19 leads to this mild childhood ailment, and causes flu-like symptoms with a rash. By body hair I mean, hair anywhere on the body, from head to toe. The normal level of C-reactive protein in an average healthy person’s blood is 4.9 milligrams per biter. cod is treated using a lot of medicines and procedures, depending upon the reason of its onslaught. Lupus Erythematosus: It is also known as a connective tissue disease.